SLM124 / SLAM Bio - LARVOL DELTA

SLM124: A first-in-class anti-CD84 antibody-drug conjugate demonstrates potent anti-tumor activity and favorable tolerability in hematologic malignancy models (ASH 2025) - "SLM124 is a highly potent, first-in-class humanized IgG1 anti-CD84 ADC that precisely targetsCD84-expressing hematologic cancer cells. It demonstrates high affinity, specific binding, potency in vitroand is well-tolerated with significant anti-tumor activity in preclinical in vivo lymphoma models. Thesecompelling preclinical data support the continued development of SLM124 as a potentiallytransformative therapeutic for patients with hematologic malignancies."

Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma